Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARDX Stock Forecast 2025-2026
$3.60
Current Price
$861.32M
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ARDX Price Targets
+316.7%
To High Target of $15.00
+191.7%
To Median Target of $10.50
+122.2%
To Low Target of $8.00
ARDX Price Momentum
-4.3%
1 Week Change
-7.2%
1 Month Change
-43.3%
1 Year Change
-29.0%
Year-to-Date Change
-55.3%
From 52W High of $8.06
+12.1%
From 52W Low of $3.21
📊 TOP ANALYST CALLS
Did ARDX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ardelyx is one of their latest high-conviction picks.
Latest ARDX Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, ARDX has a bullish consensus with a median price target of $10.50 (ranging from $8.00 to $15.00). Currently trading at $3.60, the median forecast implies a 191.7% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Louise Chen at Scotiabank, projecting a 316.7% upside. Conversely, the most conservative target is provided by Christopher Raymond at Piper Sandler, suggesting a 122.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARDX Analyst Ratings
10
Buy
1
Hold
0
Sell
ARDX Price Target Range
Low
$8.00
Average
$10.50
High
$15.00
Current: $3.60
Latest ARDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 2, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $10.00 |
| Mar 7, 2025 | Ladenburg Thalmann | Aydin Huseynov | Buy | Assumes | $11.00 |
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Outperform | Initiates | $15.00 |
| Feb 21, 2025 | Raymond James | Ryan Deschner | Strong Buy | Reiterates | $13.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $5.50 |
| Jan 27, 2025 | Piper Sandler | Christopher Raymond | Neutral | Maintains | $8.00 |
| Jan 16, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $5.50 |
| Jan 2, 2025 | Jefferies | Chris Howerton | Buy | Maintains | $8.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $5.50 |
| Nov 4, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $10.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $11.00 |
| Aug 5, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $11.00 |
| Aug 2, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $12.00 |
| Aug 2, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $11.00 |
| Jul 18, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $11.00 |
| Jul 18, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $10.00 |
| Jul 3, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $10.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| May 24, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $15.00 |
| May 24, 2024 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $15.00 |
Ardelyx Inc. (ARDX) Competitors
The following stocks are similar to Ardelyx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ardelyx Inc. (ARDX) Financial Data
Ardelyx Inc. has a market capitalization of $861.32M with a P/E ratio of 0.0x. The company generates $361.71M in trailing twelve-month revenue with a -14.9% profit margin.
Revenue growth is +61.0% quarter-over-quarter, while maintaining an operating margin of -49.0% and return on equity of -36.3%.
Valuation Metrics
Market Cap
$861.32M
Enterprise Value
$829.00M
P/E Ratio
0.0x
PEG Ratio
-51.4x
Price/Sales
2.4x
Growth & Margins
Revenue Growth (YoY)
+61.0%
Gross Margin
+83.4%
Operating Margin
-49.0%
Net Margin
-14.9%
EPS Growth
+61.0%
Financial Health
Cash/Price Ratio
+24.8%
Current Ratio
4.1x
Debt/Equity
124.7x
ROE
-36.3%
ROA
-6.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ardelyx Inc. (ARDX) Business Model
About Ardelyx Inc.
What They Do
Develops therapies for gastrointestinal disorders.
Business Model
The company focuses on creating innovative therapies to address unmet medical needs, particularly in chronic kidney disease and irritable bowel syndrome. Ardelyx generates revenue primarily through the commercialization of its lead product, tenapanor, which is designed to manage hyperphosphatemia in patients on dialysis.
Additional Information
Founded in 2007 and based in Fremont, California, Ardelyx operates in a highly regulated industry, necessitating extensive clinical trials and regulatory approvals. The company is committed to improving patient outcomes and advancing treatment options in gastrointestinal health, especially for patients with limited alternatives.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
395
CEO
Mr. Michael G. Raab
Country
United States
IPO Year
2014
Website
www.ardelyx.comArdelyx Inc. (ARDX) Latest News & Analysis
Latest News
Quick Summary
Pomerantz LLP is investigating claims for Ardelyx, Inc. (NASDAQ: ARDX) investors. Interested parties should contact Danielle Peyton for more information.
Why It Matters
The investigation by Pomerantz LLP into Ardelyx may indicate potential legal issues, which could impact the stock's performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for Ardelyx, Inc. (NASDAQ:ARDX) investors. Interested parties can contact Danielle Peyton for more information.
Why It Matters
Ardelyx investors may face potential legal issues, indicating possible financial or operational problems within the company that could impact stock performance and investor returns.
Source: Accesswire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ardelyx, Inc. - ARDX
10 days ago
Quick Summary
Pomerantz LLP is investigating claims on behalf of Ardelyx, Inc. (NASDAQ: ARDX) investors. Interested parties should contact Danielle Peyton for more information.
Why It Matters
The investigation into Ardelyx may indicate potential legal issues or financial irregularities, affecting the company's stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
13 days ago
Quick Summary
Ardelyx, Inc. has promoted Mike Kelliher to Chief Business Officer and appointed James P. Brady as Chief Human Resources Officer, enhancing its leadership team.
Why It Matters
Leadership changes can signal strategic shifts and impact company direction, potentially affecting stock performance and investor confidence in Ardelyx's future initiatives.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Ardelyx, Inc. (Nasdaq: ARDX) CEO Mike Raab will speak at the Jefferies Global Healthcare Conference on June 4, 2025, at 8:10 am ET in New York.
Why It Matters
Ardelyx's CEO's participation in a major healthcare conference highlights potential investor interest, signaling upcoming insights into the company's strategy and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky is investigating Ardelyx, Inc. (NASDAQ:ARDX) for potential federal securities law violations following its Q1 2025 financial results announcement on May 1, 2025.
Why It Matters
The investigation into Ardelyx for potential securities law violations may indicate financial irregularities, impacting stock value and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About ARDX Stock
What is Ardelyx Inc.'s (ARDX) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Ardelyx Inc. (ARDX) has a median price target of $10.50. The highest price target is $15.00 and the lowest is $8.00.
Is ARDX stock a good investment in 2025?
According to current analyst ratings, ARDX has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARDX stock?
Wall Street analysts predict ARDX stock could reach $10.50 in the next 12 months. This represents a 191.7% increase from the current price of $3.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ardelyx Inc.'s business model?
The company focuses on creating innovative therapies to address unmet medical needs, particularly in chronic kidney disease and irritable bowel syndrome. Ardelyx generates revenue primarily through the commercialization of its lead product, tenapanor, which is designed to manage hyperphosphatemia in patients on dialysis.
What is the highest forecasted price for ARDX Ardelyx Inc.?
The highest price target for ARDX is $15.00 from Louise Chen at Scotiabank, which represents a 316.7% increase from the current price of $3.60.
What is the lowest forecasted price for ARDX Ardelyx Inc.?
The lowest price target for ARDX is $8.00 from Christopher Raymond at Piper Sandler, which represents a 122.2% increase from the current price of $3.60.
What is the overall ARDX consensus from analysts for Ardelyx Inc.?
The overall analyst consensus for ARDX is bullish. Out of 13 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.50.
How accurate are ARDX stock price projections?
Stock price projections, including those for Ardelyx Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2025 10:16 AM UTC